Energy sector, upbeat vehicle sales and a recognition by the new Greek government with its immense foreign debt all put in their trends to build Tuesday trading session successful.

Crude oil was up $1.20 to $50.76 per barrel. Natural gas was down $0.01 to $2.67 per 1 million BTU. Gold was down $16.80 to $1,260.10 an ounce, while silver was down $0.06 to $17.20 an ounce. Copper was up $0.09 to $2.58 per pound.

This article generally focuses on Healthcare Sector. Few important updates related to this sector are described as under:

On Tuesday, Health care stocks were barely varied in the afternoon, with the NYSE Health Care Sector Index getting higher about 0.1% and shares of health care companies in the S&P 500 tripping about 0.2% as a group.

Ultimate Loser Of Biotech Sector: Onconova Therapeutics, (NASDAQ:ONTX), declined -36.33%, and closed at $2.55, during the last session, soon after a clinical-stage biopharmaceutical company, declared that following discussions concerning the future development of rigosertib with the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), and numerous European national regulatory agencies, the Company has solidified its schedules for a Phase 3 clinical trial for rigosertib in HR-MDS patients after failure of treatment with HMAs. Pending regulatory approvals and appropriate financing, Onconova hopes to begin trial enrollment during the second half of 2015.

Onconova Therapeutics (ONTX) a clinical-stage biopharmaceutical company focuses on discovering and developing small molecule drug candidates to treat cancer.

Along with Onconova Therapeutics, (NASDAQ:ONTX), few of the other healthcare companies’ data (along with news and profiles) that took a negative approach and proved themselves as champions, late Monday is described underneath:

Luminex Corporation (NASDAQ:LMNX) dipped -13.35%, and closed at $15.32, as Luminex Corporation, declared financial results for the fourth quarter and year ended December 31, 2014. Financial and operating highlights comprise the following:

• Consolidated fourth quarter revenue of $58.1 million, a 5 percent increase compared to the fourth quarter of 2013; full-year 2014 revenue was $227.0 million, a 6 percent increase over 2013.
• Consolidated gross profit margin was 74 percent for the fourth quarter, and 70 percent for the full year 2014.

Zogenix, Inc (NASDAQ:ZGNX) dwindled -7.25%, to settle at $1.28, after a pharmaceutical company, declared that the U.S. Food and Drug Administration (FDA) has permitted a new formulation of Zohydro(R) ER (hydrocodone bitartrate) Extended-Release Capsules, CII, with BeadTek(TM). BeadTek is a formulation technology designed to offer abuse-deterrent properties without changing the release properties of hydrocodone when Zohydro ER is used as intended.

Zogenix, Inc (ZGNX) is a pharmaceutical company committed to developing and commercializing therapies that address specific clinical needs for people living with CNS disorders who need innovative treatment alternatives to help them return to normal daily functioning.

K2M Group Holdings Inc(NASDAQ:KTWO) declined -5.16%, and closed at $18.01, as a global medical device company, declared the pricing of a follow-on offering of 6,044,990 shares of its ordinary stock at a price of $18.75 per share. K2M is selling 2,044,990 shares of ordinary stock in the offering and selling stockholders named in the registration statement are selling 4,000,000 shares of ordinary stock in the offering. In addition, certain of the selling stockholders have granted the underwriters a 30-day option from the date of the prospectus to purchase up to 906,748 additional shares of ordinary stock at the public offering price, less underwriting discounts.

K2M Group Holdings (KTWO) is a global medical device company focused on designing, developing and commercializing innovative complex spine and minimally invasive spine technologies and techniques used by spine surgeons to treat some of the most difficult and challenging spinal pathologies.

XenoPort, Inc (NASDAQ:XNPT) lowered -10.24%, and closed $7.36, during the last session, soon after a biopharmaceutical company, recently declared the pricing of $100 million aggregate principal amount of 2.50% Convertible Senior Notes due 2022 in a private placement to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended. In relationship with the offering, XenoPort also granted the initial purchasers of the notes a 30-day option to purchase up to an additional $15 million aggregate principal amount of the notes to cover over-allotments, if any. The sale of the notes closed on February 3, 2015, subject to customary closing conditions.

XenoPort, Inc (XNPT) a biopharmaceutical company, focuses on developing and commercializing a portfolio of internally discovered product candidates for the treatment of neurological and other disorders.